

Powered by:

IN-PART

Hybrid Tracer for Imaging and Surgical Guidance of Prostate Cancer

Dual labeled (Tc-99m and fluorescence) for application in radio- and fluorescence guided surgery of oligometastatic prostate cancer



Request an introduction

Reference: IDF 01-22

IP Status

Provisional patent

Source: SciePro, https://stock.adobe.com/uk/221181904, stock.adobe.com

Seeking

Licensing, Development partner

For more information, please contact:

Jonas Pollard +41 (0)79 556 20 60 jonas.pollard@chuv.ch

Background

As prostate cancer is the second most common tumorous cancer worldwide, any improvements of tracer for surgical guidance during radio/fluorescence guided resection of prostate cancer lesions are greatly sought after.

Tech Overview

A Novel hybrid tracer with superior characteristics compared to state-of-the-art alternatives.

Stage of Development

TRL 4

• In vivo biodistribution and small animals SPECT/fluorescence imaging

Benefits

- High circulation time
- High accumulation in tumor
 - Optimal signal intensity
 - Increased sensitivity

Applications

• Radio/Fluorescence guided surgery for protaste cancer

Opportunity

PACTT offers to grant exclusive or non-exclusive license to industrial partners able to develop and commercialize the technology.

Learn more about this opportunity

About IN-PART

Scientific collaborations should solve real-world problems and bring a positive impact to society. That's why we facilitate and accelerate the bench-to-bedside journey by connecting the right partners from industry and academia.

Connect is an online matchmaking platform subscribed to by **250+ universities and research institutes** to connect with industry teams in **6,000+ companies** to commercialise academic innovations and expertise that are available and seeking collaboration. <u>Create your free Connect account!</u>